Another successful peptide-based targeting multifunctional NP system that has been translated into clinical trials is BIND-014, a prostate-specific membrane antigen (PSMA)-targeted polymeric NP that contains the chemotherapy drug docetaxel for the treatment of prostate cancer [48]. This evidence concerns the gene FOLH1 and prostate carcinoma.